CliffBio
biologic

Aranesp

darbepoetin alpha

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAranesp
Active ingredientdarbepoetin alpha
Strength10MCG/0.4ML
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Aranesp patent cliff — loss of exclusivity — | CliffBio